Brief: Cantargia's Extensive Patent Protection For IL1RAP-Targeting Cancer Therapy Maintained

Cantargia AB

30/09/2021 10:33

Sept 30 (Reuters) - Cantargia AB  CANTA.ST :
    * CANTARGIA'S EXTENSIVE PATENT PROTECTION FOR
IL1RAP-TARGETING
CANCER THERAPY REMAINS IN FORCE AFTER CONCLUDED OPPOSITION
    * OPPOSITION DIVISION CONFIRMED VALIDITY OF THIS EUROPEAN
PATENT
AND REJECTED OPPOSITION
    * CANTARGIA'S EXTENSIVE PATENT PROTECTION FOR
IL1RAP-TARGETING
THERAPY IS THUS FULLY MAINTAINED WITH UNCHANGED CLAIM SCOPE.

Source text for Eikon:  ID:nWkrbMSKKd 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))